BTIG Reiterates a Buy Rating on Pliant Therapeutics (PLRX)

BTIG analyst Thomas Shrader reiterated a Buy rating on Pliant Therapeutics (PLRXResearch Report) on July 10 and set a price target of $51.00. The company’s shares closed last Wednesday at $18.75.

According to TipRanks.com, Shrader is a 1-star analyst with an average return of -2.9% and a 30.6% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Minerva Neurosciences, Aldeyra Therapeutics, and Athira Pharma.

Currently, the analyst consensus on Pliant Therapeutics is a Strong Buy with an average price target of $43.71, an 119.4% upside from current levels. In a report issued on July 11, Cantor Fitzgerald also maintained a Buy rating on the stock with a $36.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $28.02 and a one-year low of $3.97. Currently, Pliant Therapeutics has an average volume of 1.72M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.

Read More on PLRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed